



GENERAL INFORMATION

The European Directorate for the Quality of Medicines and Healthcare (EDQM) of the Council of Europe (CoE) is conducting a survey with the aim to assess various issues that Blood Establishments (BEs) in Europe might be facing.

Blood Establishments are key actors in the blood system. Therefore, it is important for the EDQM to evaluate your needs and constraints and hear your opinion on different aspects of blood transfusion.

This survey should help the EDQM to adapt its activities dedicated to Blood Establishments, and in particular the Blood Quality Management Programme (B-QM) (B-QM webpage).

It should also allow the EDQM in disseminating information to stakeholders on the obstacles blood establishments are facing.

Finally, it should help updating/harmonising quality management and regulatory policies in Europe and improve mutual confidence between blood establishments.

We would really be grateful if you, as Director or QA Manager of your Blood Establishment could take the time to reply to this questionnaire.

We recognise that this survey is substantial. However, a high participation rate in the survey might really support EDQM to voice Blood establishments' concerns.

We would also like to remind you that a similar survey was carried out in 2012, which enabled the EDQM to develop the B-QM activity.

Individual questionnaires will be kept confidential at the EDQM. If data is used from this survey outside of the EDQM or in reports, this will be done in anonymised form.

Many thanks in advance for your collaboration!





1. CONTACT DETAILS

Contact details will only be used as means of contacting if further details are necessary. The
results of this survey will be treated and presented in an anonymous way.

Contact details will only be used as n results of this survey will be treated a	neans of contacting if further details are necessary. The and presented in an anonymous way.
* 1.1. Your profile	
First Name & Last Name	
Email Address	
* 1.2. Function	
Director of the blood establishment	Quality Manager
* 1.3. Your Blood Establishment	
Name of the Blood Establishment	
Address (Street, City, Post Code)	
Country	





2. ACTIVITY PROFILE OF YOUR BLOOD ESTABLISHMENT

* 2.1. Is your Blood Establishment part of and	other blood establishment/bigger entity ?	
Yes		
No		
If yes,please specify :		
* 2.2. Your blood establishment is :		
Public (or belonging to the Ministry of Health)		
Supranational (e.g. Red Cross)		
Private		
Hospital based		
Other, please specify :		
* 2.3. How many (please enter numerical val	ue e.g. 10500):	
Whole blood donations do you have per year		
Apheresis donations do you have per year		
Donors do you have per year		
Full-time equivalent employees (FTEs) does your blood establishment have		
biood establishment have		

* 2.4. What is your activity	profile:		
Blood Collection		Blood Storage	
Blood Testing		Blood Release and Distri	bution
Blood Component Prepara	ation/ Processing	Blood Issuing (Issuing me	eaning compatibility testing)
Apheresis Component Pre	eparation/ Processing	Immuno-hematology test	ing for blood recipients
Other, please specify :			
	g activities delocalised (part d (external service), if not pl	-	
	Delocalised		Subcontracted
Blood Collection (e.g. external collection sites/mobile sites)			
Blood Testing			
Blood Component Preparation/ Processing	\bigcirc		
Apheresis Component Preparation/ Processing	\bigcirc		
Blood Storage			
Blood Release and Distribution			
Blood issuing (issuing meaning compatibility testing)			
Immuno-haematology testing for blood recipients			
	erform in your laboratory to vailable methods or in-hous		
	Commercial Method	In-house Method	Mandatory
Anti-HIV-1/2			
Combo Ag/Ab HIV			
Anti-HCV			
Combo Ag/Ab HCV			
Anti-HBc			

Anti-HBs HBsAg	HBsAg	HBsAg		Commercial Method	In-house Method	Mandatory
Anti-CMV	Anti-CMV	Anti-CMV Anti-Treponema (Syphilis) Anti-Malaria Anti-Malaria NAT-HCV NAT-HIV NAT-HBV NAT-HBV NAT-B19 Other NAT assays, please specify below (e.g. WNV) Blood grouping (ABO) Rhesus phenotyping Antibody screening Platelet count White cell count White cell count F VIII assay Haemoglobin Hematocrit pH Total protein	Anti-HBs			
Anti-HTLV Anti-Treponema (Styphilis) Anti-Malaria INAT-HCV INAT-HIV INAT-HBV INAT-HBV INAT-B19 INAT	Anti-HTLV Anti-Treponema (Styphilis) Anti-Malaria INAT-HCV INAT-HIV INAT-HBV INAT-HBV INAT-B19 INAT	Anti-HTLV Anti-Treponema (Syphilis) Anti-Malaria NAT-HCV NAT-HIV NAT-HBV NAT-HBV NAT-B19 Other NAT assays, please specify below (e.g. WNV) Blood grouping (ABO) Rhesus phenotyping Antibody screening Platelet count White cell count White cell count F VIII assay Haemoglobin Hematocrit pH Total protein	HBsAg			
Anti-Treponema (Syphilis) Anti-Malaria INAT-HCV INAT-HIV INAT-HBV INAT-HBV INAT-HBY INAT-B19 INAT-B1	Anti-Treponema (Syphilis) Anti-Malaria INAT-HCV INAT-HIV INAT-HBV INAT-HBV INAT-HBY INAT-B19 INAT-B1	Anti-Treponema (Syphilis) Anti-Malaria NAT-HCV NAT-HIV NAT-HBV NAT-HBV NAT-B19 Other NAT assays, please specify below (e.g. WNV) Blood grouping (ABO) Rhesus phenotyping Antibody screening Platelet count White cell count F Vill assay Haemoglobin Hematocrit pH Total protein	Anti-CMV			
Anti-Malaria	Anti-Mataria	Anti-Malaria	Anti-HTLV			
NAT-HCV	NAT-HCV	NAT-HCV				
NAT-HIV	NAT-HIV	NAT-HIV	Anti-Malaria			
NAT-HBV NAT-HAV NAT-B19 Other NAT assays, please specify below (e.g. WNV) Blood grouping (ABO) Rhesus phenotyping Antibody screening Platelet count White cell count Red cell count Red cell count F VIII assay Haemoglobin Hematocrit pH Total protein	NAT-HBV NAT-HAV NAT-HB19 Other NAT assays, please specify below (e.g. WNV) Blood grouping (ABO) Rhesus phenotyping Antibody screening Platelet count White cell count Red cell count Red cell count F VIII assay Haemoglobin Hematocrit pH Total protein	NAT-HBV	NAT-HCV			
NAT-HAV NAT-B19 Cother NAT assays, please specify below (e.g. WNV) Blood grouping (ABO) Rhesus phenotyping Antibody screening Platelet count White cell count Red cell count F VIII assay Haemoglobin Hematocrit pH Total protein	NAT-HAV NAT-B19 Cother NAT assays, please specify below (e.g. WNV) Blood grouping (ABO) Rhesus phenotyping Antibody screening Platelet count White cell count Red cell count F VIII assay Haemoglobin Hematocrit pH Total protein	NAT-HAV NAT-B19 Other NAT assays, please specify below (e.g. WNV) Blood grouping (ABO) Rhesus phenotyping Antibody screening Platelet count White cell count F VIII assay Haemoglobin Hematocrit pH Total protein	NAT-HIV			
NAT-B19 Other NAT assays, please specify below (e.g. WNV) Blood grouping (ABO) Rhesus phenotyping Antibody screening Platelet count White cell count F VIII assay Haemoglobin Hematocrit pH Total protein	NAT-B19 Other NAT assays, please specify below (e.g. WNV) Blood grouping (ABO) Rhesus phenotyping Antibody screening Platelet count White cell count F VIII assay Haemoglobin Hematocrit pH Total protein	NAT-B19 Other NAT assays, please specify below (e.g. WNV) Blood grouping (ABO) Rhesus phenotyping Antibody screening Platelet count White cell count F VIII assay Haemoglobin Hematocrit pH Total protein	NAT-HBV			
Other NAT assays, please specify below (e.g. WNV) Blood grouping (ABO)	Other NAT assays, please specify below (e.g. WNV) Blood grouping (ABO)	Other NAT assays, please specify below (e.g. WNV) Blood grouping (ABO)	NAT-HAV			
please specify below (e.g. WNV) Blood grouping (ABO)	please specify below (e.g. WNV) Blood grouping (ABO)	please specify below (e.g. WNV) Blood grouping (ABO)	NAT-B19			
Rhesus phenotyping	Rhesus phenotyping	Rhesus phenotyping	please specify below			
Antibody screening Platelet count White cell count Red cell count F VIII assay Haemoglobin Hematocrit DH Total protein	Antibody screening Platelet count White cell count Red cell count F VIII assay Haemoglobin Hematocrit DH Total protein	Antibody screening	Blood grouping (ABO)			
Platelet count White cell count Red cell count F VIII assay Haemoglobin Hematocrit pH Total protein	Platelet count White cell count Red cell count F VIII assay Haemoglobin Hematocrit pH Total protein	Platelet count White cell count Red cell count F VIII assay Haemoglobin Hematocrit pH Total protein	Rhesus phenotyping			
White cell count Red cell count F VIII assay Haemoglobin Hematocrit pH Total protein	White cell count Red cell count F VIII assay Haemoglobin Hematocrit D Total protein	White cell count Red cell count F VIII assay Haemoglobin Hematocrit pH Total protein	Antibody screening			
Red cell count F VIII assay Haemoglobin Hematocrit D Total protein	Red cell count F VIII assay Haemoglobin Hematocrit D Total protein	Red cell count F VIII assay Haemoglobin Hematocrit DH Total protein	Platelet count			
F VIII assay	F VIII assay	F VIII assay	White cell count			
Haemoglobin Hematocrit D Total protein	Haemoglobin Hematocrit D Total protein	Haemoglobin	Red cell count			
Hematocrit	Hematocrit	Hematocrit	F VIII assay			
pH	pH	pH	Haemoglobin			
Total protein	Total protein	Total protein	Hematocrit			
			рН			
Other tests/assay, please specify:	Other tests/assay, please specify:	Other tests/assay, please specify:	Total protein			
			Other tests/assay, please sp	ecify:		

2.7. Which tests do you perform in your laboratory for quality control of blood components?
Platelet count
White cell count
Red cell count
F VIII assay
Haematocrit
Haemoglobin
Residual leucocyte content
Haemolysis at the end of storage
Fibrogen
Other (please specify)
2.8. Which of these whole blood components do you prepare as transfusion products?
Whole blood
Whole blood, Leucocyte-Depleted
2.9. Which of these plasma components do you prepare :
Plasma, Fresh Frozen
Plasma, Fresh Frozen, Pathogen Reduced
Cryoprecipitate Plasma, Fresh Frozen, Cryoprecipitate-Depleted
Plasma, Tresm Tozen, Gryoprecipitate-Depleted

2.10. Which of these Platelet components do you prepare :
Platelets, Recovered, Single Unit
Platelets, Recovered, Pooled
Platelets, Recovered, Pooled, Leucocyte-Depleted
Platelets, Recovered, Pooled, in Additive Solution
Platelets, Recovered, Pooled, Leucocyte-Depleted,in Additive Solution
Platelets, Pooled, Pathogen reduced
Platelets, Apheresis
Platelets, Apheresis, Leucocyte-Depleted
Platelets, Apheresis, in Additive Solution
Platelets, Apheresis, Leucocyte-Depleted, in Additive Solution
Platelets, Apheresis, Pathogen-reduced
Platelets, Cryoperserved
2.11. Which of these Red Cell components do you prepare :
Red Cells
Red Cells, Buffy Coat Removed
Red Cells, in Additive Solution
Red Cells, Buffy Coat Removed, in Additive Solution
Red Cells, Leucocyte-Depleted
Red Cells, Leucocyte-Depleted in Additive Solution
Red Cells, Apheresis
Red Cells, Washed
Red Cells, Cryopreserved
2.12. Which of these blood components for intra-uterine neonatal and infant use do you prepare :
Red Cells, Leucocyte-Depleted for Intrauterine Transfusion
Platelets, Leucocyte-Depleted for Intra-uterine Transfusion
Whole Blood, Leucocyte-Depleted for Exchange Transfusion
Whole Blood, Leucocyte-Depleted, Plasma Reduced for Exchange Transfusion
Red Cells, Leucocyte-Depleted, suspended in Fresh Frozen Plasma, for Exchange Transfusion
Red Cells for Neonatal and Infant Small Volume Transfusion

2.13. Which of these other components do you prepare :
Granulocytes, Apheresis
Lymphocytes
Autologous Blood Components
Cord blood
2.14. If you provide plasma to fractionators please specify which type of plasma do you provide :
Apheresis plasma
Recovered plasma





3. QUALITY MANAGEMENT SYSTEMS/STANDARDS & REGULATION

A Quality Management System (QMS) is a defined set of interacting processes & actions to direct and control an organisation towards quality. In a Blood Establishment a QMS should encompass quality, quality control, quality assurance & continuous improvement. It should cover the following elements:

Donor Selection, Blood Collection/Testing/Processing/Issuing/Distribution; General Quality Management & Organisation; Management of Personnel; Contract Management; Management of Quality Documents; Equipment/Material/Premises; Change Control; Non-conformance(NC)/Corrective and Preventative Actions (CAPAs); Management Review; Internal auditing and Risk Management.

auditing and Risk Manage		Actions (CAPAs); Manageme	ent Review; Internal
* 3.1. With this definition in m Management System?	ind how would you rate	the current level of implemen	tation of your Quality
1. No Quality Management S	System is currently implement	ed	
2. A Quality Management Sy comment field below)	stem is partially implemented	(please provide the areas where a C	QMS is implemented in the
3. A Quality Management Sy	stem is implemented but it ne	eds to be further developed as it is	
4. A Quality Management Sy	stem is in place and is efficien	nt	
* 3.2. Which of the following states they are used on a mandate	•	our Blood Establishment and basis or not used? Volontary basis	please specify whether
			Not used
EU Directive 2002/98/EC			Not used
			Not used
2002/98/EC EU Directive			Not used
2002/98/EC EU Directive 2004/33/EC EU Directive			Not used

	Mandatory basis	Volontary basis	Not used
ISO Standard 17025			
ISO Standard 15189			
Guide to the Preparation, Use and Quality Assurance of Blood Components (CoE Guide)			
Good Practice Guidelines (GPGs) for blood establishments and hospital blood banks required to comply with the EU Directive 2005/62/EC (as a part of the 18th CoE Guide)			
WHO guidelines on GMP for Blood Establishments			
EU GMP (Medicinal Products for Human and Veterinary Use, Part I)			
EU GMP for Blood Derived Products (Annex 14)			
PIC/S Guidelines (Guide for Blood Establishments, PE 005- 3)			
National standards/guidelines			
Other, please specify :			
3.3. For which of the follow		ou certified/ accredited or on	
ISO Standards 9001	Status	A	Reason
		\$	+
ISO Standards 17025		\$	\$
ISO Standards 15189		•	\$
Other, please specify:			
Officer, piease specify.			

* 3.4. In which of the following areas do you encounter difficulties in implementing/developing your QMS?
Donor Selection
Blood Collection
Blood Testing
Blood Processing
Blood Storage
Blood Issuing
Blood Distribution
General Quality Management
Organisation (Policy, Objectives)
Mangement of Personnel (recruitment, initial & continuous training)
Management of Quality Documents
Equipment/Material/Premises (e.g. qualification, validation, selection)
Contract management
NC/CAPA Management
Internal Auditing
Change Control
Management Review
Risk Management
Other, please specify :

* 3.5. How do you rate the quality of the following standards in helping you develop/improve your QMS with regards to the following processes ?

A rating matrix is given below:

- 1 Not useful at all
- 2 Useful to a limited extent
- 3 Useful to a moderate extent
- 4 Significantly useful

		CoE Guide and Good	
	EU Blood Directives	Practice Guidelines	ISO Standards
Donor Selection, Blood Collection/Testing/Storage/Distribution/Issuing	\$	\$	\$
Management of Quality Documents	•	•	•
Equipment/Material/Premises	•	•	•
Change Control Management	•	•	•
NC/CAPA Management	\$	\$	\$
Management Review	•	•	\$
Management of Personnel	•	\$	•
Internal Auditing	•	•	•
Risk Management	\$	\$	\$





4. SELF EVALUATION OF THE LEVEL OF THE QUALITY MANAGEMENT SYSTEM IN YOUR BLOOD ESTABLISHMENT

The EDQM foresees the necessity to elaborate guidelines on specific matters to help Blood Establishments implementing their QMS. The aim of this part of the Survey is to allow to the EDQM to develop and adapt its activities to your needs (among other initiatives develop for example a manual or a guidance on how to qualify an automate etc..)

Evaluation levels:

Level 1

The stated requirement is false or the action is not done. There is no evidence of this action, the requirement is not implemented.

Level 2

The stated requirement is often false or the action is partially done. There is little evidence of the accomplished actions. The requirement is on an initial stage and there is a partial level of implementation.

Level 3

The stated requirement is true or the action is done. Evidence of a systematic approach of significant accomplishments is available. The requirement is defined, managed and implemented.

Level 4

The requirement is systematically true or the action is systematically done and optimised. There is evidence of a complete and systematic actions. The requirement is optimised and systematically implemented and optimised.

4.1. Organisation	1			
	Level 1	Level 2	Level 3	Level 4
A quality policy, objectives, and a quality manual are defined and communicated to the personnel.				
An independent quality function (Quality Manager) is in place and is responsible for the oversight of all QMS issues.				
An organisation chart/organigram is in place and, shows hierarchical structure and lines of responsibilities.				
Resources (Personnel, material/equipment) are available in sufficient number and suit the activities to be carried out.				
Quality Policy, Objectives, Quality Manual and resources are regularly reviewed and updated.				

Level 1 Level 2 Level 3 Level 4 A procedure on management review is in place and is regularly updated. Management review meetings take place regularly, involve key personnel and are documented. Management review meetings monitor the effectiveness of the OMS (Any factors affecting the quality such as non-conformities, complaints are discussed and effectiveness of actions are monitored). After management review meetings, actions (CAPA) are identified, planned and implemented.	4.2. Managemer	nt Review			
management review is in place and is regularly updated. Management review meetings take place regularly, involve key personnel and are documented. Management review meetings monitor the effectiveness of the QMS (Any factors affecting the quality such as nonconformities, complaints are discussed and effectiveness of actions are monitored). After management review meetings, actions (CAPA) are identified, planned and		Level 1	Level 2	Level 3	Level 4
meetings take place regularly, involve key personnel and are documented. Management review meetings monitor the effectiveness of the QMS (Any factors affecting the quality such as non- conformities, complaints are discussed and effectiveness of actions are monitored). After management review meetings, actions (CAPA) are identified, planned and	management review is in place and is regularly				
meetings monitor the effectiveness of the QMS (Any factors affecting the quality such as non- conformities, complaints are discussed and effectiveness of actions are monitored). After management review meetings, actions (CAPA) are identified, planned and	meetings take place regularly, involve key personnel and are				
review meetings, actions (CAPA) are identified, planned and	meetings monitor the effectiveness of the QMS (Any factors affecting the quality such as non- conformities, complaints are discussed and effectiveness of actions				
	review meetings, actions (CAPA) are identified, planned and				

4.3. Personnel				
	Level 1	Level 2	Level 3	Level 4
Job descriptions, with clear tasks and responsibilities, are in place for all personnel.				
Procedure(s) for recruitment, initial and continuous training of the personnel is/are in place. It covers approach to training, its contents and its evaluation and effectiveness.				
Training plans are in place, training records are maintained for all personnel.				
Training programmes are periodically assessed and competence of personnel evaluated regularly.				
When non-conformities related to lack of training are found, actions (CAPA) are identified, planned and implemented.				

4.4. Equipment,	Material and	l Premises		
	Level 1	Level 2	Level 3	Level 4
Procedures on qualification, validation, calibration, maintenance are in place and regularly updated.				
All equipment, methods, premises are regularly validated, qualified, calibrated and maintained.				
Qualification/validation comprises Design, Installation, Operational and Performance Qualification.				
Validation master plans or equivalent are defined. Results of validation/qualification, maintenance, calibration are documented and reviewed.				
When defect material, equipment malfunctions, failures are found, actions (CAPA) are identified, planned and implemented.				

4.5. Quality Docu	mentation	Management		
	Level 1	Level 2	Level 3	Level 4
A document control system, defined in a procedure is established for review, revision history and archiving of documents.				
Quality documents are uniquely identifiable, approved, signed and dated by an authorised person. Non-controlled copies are prevented.				
Training is performed against procedures and procedures are available on the effective date.				
All significant changes to quality documents are acted upon promptly, are reviewed, dated and signed by an authorised person.				

4.6. Supplier Qua	alification an	d Contract Mai	nagement	
	Level 1	Level 2	Level 3	Level 4
Procedures on Contract management and supplier management is in place and is regularly updated.				
All tasks performed externally (e.g. purchasing of material, external testing, transport by hospitals) are defined in a contract. All duties and responsibilities of each party are defined.				
Purchasing of equipment/material is documented. User Specifications Requirements (USR) are defined for all equipment/material.				
All suppliers and subcontracted parties are evaluated and audited.	\bigcirc			
When problems related to contract, suppliers, subcontracted parties are found, actions (CAPA) are identified, planned and implemented.				

4.7. Selection of	donors and	collection		
	Level 1	Level 2	Level 3	Level 4
Procedures for safe identification of donors, suitability interview, and eligibility assessment are implemented and updated.				
Procedures for blood collection ensure that the identity of the donor is checked, that link between donor and blood components is established, actions take place following unsuccessful donation, risk of misidentification and mix up is avoided.				
Blood collection procedure minimise risk of microbial contamination; the disinfection procedure is validated.				
When problems related to donor selections and blood collection are found, actions (CAPA) are identified, planned and implemented.				

4.8. Testing				
	Level 1	Level 2	Level 3	Level 4
Procedures describing testing activities, handling donors specimens, sampling, analysis and data processing are in place.				
Screening algorithms are defined in procedures for all tests performed.				
The performance of the laboratory is assessed regularly by participation in formal external quality assessment/proficiency testing programme for all tests carried out in the laboratory.				
When problems related testing, discrepant results are found; actions (CAPA) are identified, planned and implemented.				

.9. Processing 8				
	Level 1	Level 2	Level 3	Level 4
Procedures describing processing and release of blood components are defined and regularly updated.				
All processes related to processing are validated to ensure the quality of blood components.				
Released and non- released components are physically and administratively segregated.	0			
When non-conformities related processing and release are found, actions (CAPA) are identified, planned and implemented.				
l.10. Storage & I	Distribution Level 1	Level 2	Level 3	Level 4
		Level 2	Level 3	Level 4
Procedures describing storage and distribution are defined and		Level 2	Level 3	Level 4
Procedures describing storage and distribution are defined and regularly updated. All processes related to storage and distribution are validated to ensure the quality of blood components during the entire storage, distribution and exclude		Level 2	Level 3	Level 4

l.11. Internal Au	aitiiig			
	Level 1	Level 2	Level 3	Level 4
Procedures on internal audits/self-inspections are in place and regularly updated.				
Internal audits/self- inspection are performed regularly by trained and competent persons, in an independent way.				
Outcomes of internal audits/self-inspections are reviewed and documented.				
When non-conformities are found during audits, actions (CAPA) are				
identified, planned and implemented.	rmities and (CAPA Manager	nent Level 3	Level 4
implemented.		_		Level 4
Procedures on management of non-conformance and CAPA are in place and are		_		Level 4

4.13. Change Co	ntrol			
+. 10. Onange 00				
T	Level 1	Level 2	Level 3	Level 4
There is a formal change control system in place to plan, evaluate and documents all changes that may affect processes and the quality and safety of blood components				
Procedures for change control are in place and are regularly updated.				
1.14. Risk manaç		Level 0	1 12	Lovel
There is policy in place	Level 1	Level 2	Level 3	Level 4
on risk quality management.				
Risk based decision making is used in various area such as change control, validation/qualification and investigations of non-conformities.				





5. TARGETING THE NEEDS OF YOUR BLOOD ESTABLISHMENT

5.1. What are the main obstacles you are facing to implement regulatory requirements and a Quality Management System?
Lack of financial resources
Inappropriate financial resources
Lack of Human resources
Inappropriate Human resources
Lack of equipment/material
Inappropriate equipment/material
Lack of educational support (e.g. guidelines, trainings)
Inappropriate educational support (e.g. guidelines, training)
Difficulties to implement legislation (e.g. ambiguous, unclear requirements)
Other, please specify:
5.2. Do you feel a lack of the following support from you competent authority?
Financial resources
Material/equipment
Educational support
Legislation
Other, please specify :

	State financing (Competent Authority/Ministry)
	Self-financing by selling of blood components or blood products to hospitals
	Self-financing by selling of plasma to fractionators
	Other, please specify:
	Which requirements of the EU Directives/Legislation are the most difficult to implement, is ambiguous
or n	eed to be further clarified?
Plea	ase specify and indicate the reason
5 5	Are you able to meet the demands in components from the hospitals/clinics?
).ວ.	
	Yes
	No
	If No, please specify:
5.6.	
\neg	If you throw away/discard unused plasma, what type of plasma do you throw away/discard?
	If you throw away/discard unused plasma, what type of plasma do you throw away/discard ? Recovered plasma
	Recovered plasma
	Recovered plasma Apheresis plasma
	Recovered plasma Apheresis plasma
5.7.	Recovered plasma Apheresis plasma Please specify how many liters/year on average :
5.7.	Recovered plasma Apheresis plasma Please specify how many liters/year on average: If you are unable to sell plasma to fractionators, what are the main reasons?
5.7.	Recovered plasma Apheresis plasma Please specify how many liters/year on average: If you are unable to sell plasma to fractionators, what are the main reasons? Lack or no acess to fractionation facilities
5.7.	Recovered plasma Apheresis plasma Please specify how many liters/year on average: If you are unable to sell plasma to fractionators, what are the main reasons? Lack or no acess to fractionation facilities Financial issues
5.7.	Recovered plasma Apheresis plasma Please specify how many liters/year on average: If you are unable to sell plasma to fractionators, what are the main reasons? Lack or no acess to fractionation facilities Financial issues Level of QMS
5.7.	Recovered plasma Apheresis plasma Please specify how many liters/year on average: If you are unable to sell plasma to fractionators, what are the main reasons? Lack or no acess to fractionation facilities Financial issues Level of QMS Safety issues (e.g. NAT testing, epidemiology issues) please specify below
5.7.	Recovered plasma Apheresis plasma Please specify how many liters/year on average: If you are unable to sell plasma to fractionators, what are the main reasons? Lack or no acess to fractionation facilities Financial issues Level of QMS

	Whole Blood Donors	Apheresis Donors
Reimbursement of medical costs		
Direct payment (e.g. money, cheques)		
Compensation linked to loss of earnings/ salary		
Food vouchers		
Free physical check-up		
Time off work, private sector		
Small tokens (mugs, t-shirts etc)		
Refreshments		
Other forms of		
compensation Please specify: 5.9. Is there any national leg	islation in place, which harmonises the	e type and amount of
Please specify : 5.9. Is there any national leg ncentives/compensations th		e type and amount of
Please specify: 5.9. Is there any national leg ncentives/compensations th Yes No		e type and amount of
Please specify : 5.9. Is there any national leg ncentives/compensations th		e type and amount of
Please specify: 5.9. Is there any national leg ncentives/compensations th Yes No		e type and amount of
Please specify: 5.9. Is there any national leg ncentives/compensations th Yes No f yes, please specify:		e type and amount of
Please specify: 5.9. Is there any national leg ncentives/compensations th Yes No f yes, please specify:	at are allowed ?	e type and amount of
Please specify: 5.9. Is there any national leg ncentives/compensations th Yes No f yes, please specify:	at are allowed ?	e type and amount of
Please specify: 5.9. Is there any national leg ncentives/compensations th Yes No f yes, please specify: 5.10. Do you encounter a de	at are allowed? crease in the usage of red cells?	e type and amount of
Please specify: 5.9. Is there any national leg ncentives/compensations th Yes No f yes, please specify: 5.10. Do you encounter a de Yes No	at are allowed? crease in the usage of red cells?	e type and amount of
Please specify: 5.9. Is there any national leg ncentives/compensations th Yes No f yes, please specify: 5.10. Do you encounter a de Yes No	at are allowed? crease in the usage of red cells?	e type and amount of





6. THANKS!

Thank you very much for taking time in replying to this survey.

Do not hesitate to contact us (EDQM_B_QM@edqm.eu) if you would like to receive further information or provide us with additional information.

If you are interested in participating in B-QM activities please visit our webpage $\underline{\text{B-QM webpage}}$ this activity is free of costs and aims at supporting BEs .

By clicking on the "Submit" button below, you will definitely submit your answers.